# Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

> **NCT01449591** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Erythemato-telangiectatic Rosacea

## Interventions

- **DRUG:** BFH772 1% ointment
- **DRUG:** Vehicle ointment
- **DRUG:** Noritate® 1% cream

## Key facts

- **NCT ID:** NCT01449591
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01449591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01449591, "Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01449591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*